Nerve Block for Post-Surgery Pain
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate if the use of a bilateral nerve block with a local anesthetic (ropivacaine), as part of a standard of care pain control regimen (called multimodal analgesia \[MMA\]), has a favorable effect on our institutional MMA pain regimen. Subjects will go through the following study procedures: review of medical history and medications subjects have taken within a month prior to surgery. Subjects will be randomly assigned to one of the two study groups (1:1) to receive either, an ultrasound-guided bilateral nerve block (called "Pecto-Intercostal Fascial Block \[PIFB\]") with ropivacaine or saline 0.9 solution, in addition to our institutional MMA regimen. A baseline line pain and nausea scores will be recorded before surgery. The block will be performed right after general anesthesia induction. The details about the surgery will be collected. Pain assessments, nausea and vomiting scores will be registered at 12, 24 and 48 hours after surgery as well. Lastly, a follow up phone call will be made by the research team to conduct a pain-detect questionnaire at 30, 60 and 90 days after surgery.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, your medical history and medications taken within a month prior to surgery will be reviewed, so it's best to discuss this with the trial team.
What data supports the effectiveness of the treatment Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine for post-surgery pain?
Is the Pecto-intercostal Fascial Block safe for humans?
How does the nerve block treatment for post-surgery pain differ from other treatments?
The nerve block treatment, specifically the pecto-intercostal fascial block (PIFB), is unique because it targets the anterior branches of intercostal nerves to manage pain, particularly in cardiac surgery patients. Unlike traditional pain management methods, PIFB is administered using ultrasound guidance to provide targeted pain relief, potentially reducing the need for opioids and minimizing side effects.12357
Eligibility Criteria
This trial is for individuals undergoing open heart surgery, who can have their medical history and medication use reviewed. They must be able to receive a nerve block in addition to standard pain control methods. There's no information on who cannot participate provided here.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a bilateral nerve block with ropivacaine or saline during open-heart surgery
Postoperative Monitoring
Pain, nausea, and vomiting scores are assessed at 12, 24, and 48 hours after surgery
Follow-up
Participants are monitored for pain-DETECT scores at 30, 60, and 90 days after surgery
Treatment Details
Interventions
- Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine
- Pecto-intercostal Fascial Block with normal saline
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University
Lead Sponsor